Tuesday, January 1, 2019

Shilpa Medicare gets USFDA nod for cancer treatment injection

Shilpa Medicare gets USFDA nod for cancer treatment injection The company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL injection USP in the strengths 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials, Shilpa Medicare said in a BSE filing.

from Moneycontrol Business News http://bit.ly/2QeZD2x
at
Labels: , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

LTIMindtree Q4 Preview: Lower pass-through revenue seen impacting growth marginally

A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...